To mechanistically prove that BECLIN-1-dependent autophagy may sensitize DLBCL cells to chemotherapy, we chose three DLBCL cell lines with different genetic backgrounds of BECN1 and BCL2 and we compared their responses to doxorubicin-induced cell toxicity. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.